Vitamin K News and Research RSS Feed - Vitamin K News and Research

Vitamin K is a nutrient that the body needs in small amounts to function and stay healthy. Vitamin K helps to form blood clots (a mass that forms when blood platelets, proteins, and cells stick together) and maintain strong bones. It is fat-soluble (can dissolve in fats and oils) and is found in green leafy vegetables, broccoli, liver, and vegetable oils. Vitamin K is also made by bacteria that live in the large intestine. Not enough vitamin K can lead to bleeding and bruising. It is a type of phylloquinone.
Morbidity, mortality of AF patients remains high at 1 year even with good use of oral anticoagulants

Morbidity, mortality of AF patients remains high at 1 year even with good use of oral anticoagulants

Mortality and morbidity of atrial fibrillation (AF) patients remains high at one year despite good use of oral anticoagulants, according to the one year follow up of the Atrial Fibrillation General Pilot Registry. [More]
Recommendations on arrhythmia management in ACS patients published in EP Europace

Recommendations on arrhythmia management in ACS patients published in EP Europace

The first multidisciplinary recommendations on the management of arrhythmias in patients with acute coronary syndromes (ACS) are published today in EP Europace. [More]
Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Janssen Research & Development, LLC and its development partner, Bayer HealthCare, announced today the expansion of the EXPLORER global cardiovascular research program for XARELTO (rivaroxaban) to include additional high-risk patient populations. [More]
Armetheon raises $7 million in first round of financing

Armetheon raises $7 million in first round of financing

Armetheon, Inc., a biopharmaceutical company focused on developing novel mid- to late-stage cardiovascular drug candidates, today announced that it has raised $7.0 million in its first round of financing. [More]
Experts to debate healthy labor and delivery practices at Cedars-Sinai Birth Community Day

Experts to debate healthy labor and delivery practices at Cedars-Sinai Birth Community Day

Doctors, nurses, midwives and doulas will debate healthy labor and delivery practices - including the use of the synthetic hormone Pitocin to hasten childbirth and vitamin K to speed blood clotting in newborns -- at the third annual Cedars-Sinai Birth Community Day, Aug. 14. [More]
New supplement covers current knowledge and methods for management of AAICH

New supplement covers current knowledge and methods for management of AAICH

The Journal of Neurosurgery is pleased to announce today's publication of a supplement to the August issue entitled "Race Against the Clock: Overcoming Challenges in the Management of Anticoagulant-Associated Intracerebral Hemorrhage. [More]
Endocrine Society announces winners of Early Investigators Awards and FLARE Internship Awards

Endocrine Society announces winners of Early Investigators Awards and FLARE Internship Awards

The Endocrine Society is pleased to announce the recipients of the 2014 Early Investigators Awards and the Future Leaders Advancing Research in Endocrinology Internship Awards. [More]
Armetheon reaches agreement with FDA on SPA for final pivotal trial of tecarfarin

Armetheon reaches agreement with FDA on SPA for final pivotal trial of tecarfarin

Armetheon, Inc., today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the final pivotal trial of tecarfarin. [More]
Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE). [More]
Healthy Directions launches Krill Omega Defense

Healthy Directions launches Krill Omega Defense

Healthy Directions, LLC, today announced the launch of Krill Omega Defense™, a unique krill supplement formulated by Julian Whitaker, MD, that supports and maintains the health of the body's key biological functions and systems—from the heart, brain, and nerves to the eyes and bones. [More]
ESC presents results of pilot registry on management and treatment of AF in Europe

ESC presents results of pilot registry on management and treatment of AF in Europe

Results for a pilot registry on the management and treatment of atrial fibrillation in Europe were presented yesterday by the European Society of Cardiology. AF is the commonest cardiac rhythm disorder and each of us have a one-in-four lifetime risk of developing it. Statistics show that oral anticoagulant use has increased, but new oral anticoagulant use is still low. Authors also concluded that compliance with treatment guidelines for patients with the lowest and higher stroke risk scores remains suboptimal. [More]
Pfizer, Octapharma AG to market investigational agent for urgent reversal of vitamin K antagonist

Pfizer, Octapharma AG to market investigational agent for urgent reversal of vitamin K antagonist

... [More]

New study guides clinicians and policy makers on cost-effectiveness of anticoagulant drugs

Patients who are responding below par to the anticoagulant drug warfarin have several options. They can undergo even more blood tests to monitor their response to the different dosages of this medication which is prescribed to prevent strokes, or they could start using one of the newer, yet more expensive, anticoagulants on the market. [More]
Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Janssen Pharmaceuticals, Inc. announced today a newly published, pooled analysis of the Phase III EINSTEIN trial program, showing XARELTO (rivaroxaban) is as effective as the standard of care in reducing the risk of deep vein thrombosis and pulmonary embolism in people with symptomatic DVT or PE, while reducing the incidence of major bleeding by 46 percent. [More]
Research: General practitioners undertreat women with atrial fibrillation

Research: General practitioners undertreat women with atrial fibrillation

General practitioners (GPs) undertreat women with atrial fibrillation (AF), according to research presented at ESC Congress 2013 today by Dr Pierre Sabouret from France. The analysis of more than 15,000 patients showed that women were undertreated with antithrombotic medications compared to men regardless of their stroke risk and comorbidities. [More]
Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital, an internationally recognized teaching affiliate of Harvard Medical School known for its excellence in patient care, medical research and training of outstanding young health professionals. [More]
Clot-inhibiting drug apixaban shows added benefits in adults with non-valvular atrial fibrillation

Clot-inhibiting drug apixaban shows added benefits in adults with non-valvular atrial fibrillation

The clot-inhibiting drug apixaban (trade name: Eliquis) has been approved in Germany since November 2012 for the prevention of embolism and stroke in adults with non-valvular atrial fibrillation. [More]
Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration has accepted for review a Supplemental New Drug Application for Eliquis (apixaban), for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, in adult patients who have undergone hip or knee replacement surgery. [More]
Kcentra gets FDA approval for adults with acute major bleeding

Kcentra gets FDA approval for adults with acute major bleeding

The U.S. Food and Drug Administration today approved Kcentra (Prothrombin Complex Concentrate, Human) for the urgent reversal of vitamin K antagonist anticoagulation in adults with acute major bleeding. [More]

FDA approves Octapharma USA's BLA for octaplex

The U.S. Food and Drug Administration has accepted Octapharma USA's Biological License Application for octaplex. [More]